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Abstract: The goal of this study was to determine if selected mycotoxins (trichothecenes, 
aflatoxins, and ochratoxins) could be extracted and identified in human tissue and body 
fluids from patients exposed to toxin producing molds in their environment. Human urine 
and methanol extracted tissues and sputum were examined. Trichothecenes were tested 
using competitive ELISA techniques. Aflatoxins B1, B2, G1, and G2, and ochratoxin A 
were tested by using immunoaffinity columns and fluorometry. Test sensitivity and 
specificity were determined. Levels of detection for the various mycotoxins varied from 
0.2 ppb for trichothecenes, 1.0 ppb for aflatoxins, and 2.0 ppb for ochratoxins. 
Trichothecene levels varied in urine, sputum, and tissue biopsies (lung, liver, brain) from 
undetectable (<0.2 ppb) to levels up to 18 ppb. Aflatoxin levels from the same types of 
tissues varied from 1.0 to 5.0 ppb. Ochratoxins isolated in the same type of tissues varied 
from 2.0 ppb to > 10.0 ppb. Negative control patients had no detectable mycotoxins in 
their tissues or fluids. These data show that mycotoxins can be detected in body fluids 
and human tissue from patients exposed to mycotoxin producing molds in the 
environment, and demonstrate which human tissues or fluids are the most likely to yield 
positive results.  
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1. Introduction 
 
Over the past 15-20 years, toxic mold exposure has become hazardous and frequent [1]. Scientific 
and medical literature has increased the awareness of mycotoxin producing fungi as possible 
pathogens in human disease [2,3]. After hurricane Katrina, the Center for Disease Control (CDC) 
issued new revised warnings as to the severe health effects of mycotoxin producing mold exposure [4]. 
Until now, there has been no readily available test to clinicians for helping establish the diagnosis of 
infections or illness due to toxin producing mold exposure. Currently, tests such as a sandwich enzyme 
linked immunosorbant assay (ELISA) test for antibodies to Aspergillus and polymerase chain reaction 
(PCR) for the detection of mold DNA in human specimens have been limited to clinical research 
investigating mold infections in immune-compromised patients (cancer, HIV, etc)  [5,6]. There is a 
need to know not only if mycotoxin-producing molds are in the patient’s environment, but if these 
molds and their toxins are present in the patient, which could potentially be causing their   
medical problems.  
Immunology tests such as competitive ELISA and immunoabsorbant (IA) columns utilize the 
concept of antigen-antibody reactions to capture and identify the antigen (a specific mycotoxin) by 
spectroscopy or fluorometry [7,8] and make it possible for the instant detection of mycotoxins from 
toxin producing or infectious molds.  
Other work has demonstrated that mycotoxins can be detected in human sera [9-13] and in animal 
tissue [14]. Recently, work in China has been presented showing that plasma levels of aflatoxin B1 can 
be found in adolescents, which may impose substantial risk for hepatocarcinogenesis in adulthood 
[15]. Also, Tang [16] demonstrated that aflatoxin B1 can be determined in the serum. Ochratoxin A 
can also be measured in urine [17]. Additionally, trichothecenes can be found in urine [18].  However, 
our study is the first to examine large numbers of body fluids and tissue for the presence of mycotoxins 
in patients who have knowingly been exposed to environmental toxin producing molds. The findings 
presented in this study may also be helpful in identifying which tissues and/or fluids may be best for 
examination when trying to identify specific mycotoxins.  
This study demonstrates that ELISA plates and IA columns can be adapted for human testing to 
evaluate the presence of mycotoxins. The mycotoxins studied were the aflatoxins, ochratoxins, and 
macrocyclic trichothecenes [19]. Validations were conducted in a CLIA (Clinical Laboratory 
Improvement Act of 1988) certified lab on patients with known exposure to mycotoxins or 
environmental molds and patients with no known exposure to the same. We demonstrate that 
competitive ELISA tests and IA columns can be used to evaluate tissues and fluids from patients who 
have been exposed to mycotoxin producing molds in the environment. The mycotoxin detection assays 
utilized specific mycotoxins to generate a qualitative determination of the presence or absence of 
fungal mycotoxins in clinical fluid and tissue.  
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2. Results and Discussion  
  
In order to determine the limits of detection possible with our testing techniques a number of 
controls were developed. Validation results also tested accuracy, precision, level of detection (LOD), 
and interfering substances. Samples were also analyzed for matrix affect. Validations were conducted 
using CLSI (EP17 [20], EP5-A2 [21], and EP15-A2 [22]) specification. All criteria obtained were 
acceptable by CLIA standards. The “within-run” or “within-day” values all had standard deviations 
(SD) < 0.2. The “between- day” values all had reportable SDs of < 0.3. Interfering substances were not 
detected. Only level of detection (LOD) was determined in this study because this is a qualitative test 
only and actually obtained quantitative values are not reported. The importance of the quantitative 
amounts is yet to be ascertained and is not a part of these studies.  The controls were samples of urine, 
nasal secretions, and tissue samples spiked with known amounts of the different mycotoxins being 
studied. Prior to spiking the samples, all samples were tested and demonstrated no detectable 
mycotoxins. As result of that testing and analysis, the lowest concentration of mycotoxin which could 
be detected was determined. Levels of detection of mycotoxins in human specimens reported in parts 
per billion (ppb) or ng/mL were determined to be > 1.0 for aflatoxins, >2.0 for ochratoxins, and > 0.2 
for trichothecenes.   
Specimens from patients with no known toxic mold exposures were tested to develop a set of 
reference data for a control group. The mycotoxin levels detected in the negative control group by 
specimen type is shown in Table 1. In urine samples, trichothecene levels were less that 0.2 ppb (mean 
equal to 0.08 ppb) and aflatoxin and ochratoxin levels were less than 1.0 and 2.0 ppb, respectively. In 
samples of nasal secretions, trichothecene levels were less than 0.2 ppb (mean equal to 0.12 ppb) 
while, the aflatoxin and ochratoxin levels were less than 1.0 and 2.0 ppb, respectively. In body tissues, 
trichothecene levels were less than 0.2 ppb (mean equal to 0.09 ppb) and again aflatoxin and 
ochratoxin levels were less than 1.0 and 2.0 ppb, respectively. All specimens were evaluated for the 
matrix effect (evaluating the components of a sample other than the analyte). Through the validation 
procedures, urine trichothecenes were diluted 1:5, while aflatoxins and ochratoxin A were diluted 1:7. 
Nasal secretions and tissue extracts showed no matrix affect.  
 
Table 1. Mycotoxin values (in ng/mL (ppb)) by specimen in negative control group. 
           Trichothecenes     Aflatoxins       Ochratoxins 
Specimen type                n 
  Urine       55      < 0.2 ppb            < 1.0 ppb             < 2.0 ppb 
       Mean:  0.08  ppb     
 
  Nasal Secretions  27            < 0.2 ppb            < 1.0 ppb             < 2.0 ppb  
         Mean:  0.12  ppb   
 
  Tissue      15          < 0.2 ppb           < 1.0 ppb            < 2.0 ppb  
         Mean:  0.09  ppb 
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Urinary data for all mycotoxins were calculated as nanograms per milliliter (parts per billion). 
Independent samples t-tests were performed on both the raw and log transformed datasets. The Mann 
Whitney U test, a non-parametric test, was also performed on both the raw and log transformed 
datasets. All data evaluated in all sets of mycotoxins showed a significant difference in levels by  
group (p<0.005).  
The sensitivity and specificity of the various mycotoxin tests were determined, see Table 2. The 
sensitivity of our assay varied for both the type of mycotoxin and the sample being tested. For the 
detection of trichothecenes in urine, nasal secretions and body tissue, sensitivity varied from 44.4% to 
94.5%. All samples were significantly different (p<0.005) from the control group. For aflatoxins in 
fluids and tissues, the sensitivity values varied from 17.4% to 70.6% (p<0.005) and for ochratoxin 
detection, the sensitivity values varied from 14.3% to 17.4% (p< 0.005). However, the specificity was 
100% in all cases. The specimens were submitted by physicians in an attempt to rule mycotoxin 
exposure in or out. The symptoms acknowledged by physicians as being related to mycotoxin/mold 
exposure are considered by some to be vague. These include such symptoms as asthma, memory loss, 
fatigue, headache, muscle pains,or weakness. Many patients may carry a diagnosis of chronic fatigue 
syndrome, chronic asthma, muscular dystrophy, autism or dementia. Thus, a screening test may prove 
useful for patient care, especially if the test is negative. If a patient exhibits symptoms, the likelihood 
of having mycotoxin exposure increases (sensitivity) as can be seen in Table 2. Our data show that the 
likelihood of finding the toxins in human body tissues and/or fluids is greatest in urines for all toxins 
tested. The sensitivity for aflatoxins and ochratoxins is lower in all tissues. Our testing methods can 
detect those toxins (specificity) if they are present at the limit of detection.  
 
Table 2.  Sensitivity and Specificity of Mycotoxin Tests. 
                          Sensitivity   Specificity  
Trichothecenes  
      Urines            94.5 %      100 % 
      Nasal Secretions                44.4%       100 % 
      Tissue             58.8 %      100% 
Aflatoxins     
      Urines             70.6%       100 % 
      Nasal Secretions         17.4%       100 % 
      Tissue                             40.0 %      100 % 
Ochratoxins  
      Urine             17.4%       100% 
      Nasal Secretions                   ND 
a        ND  
      Tissue            14.3 %      100%  
a ND = not detected
 
Tables 3 and 4 demonstrate the aflatoxin and ochratoxin levels in patient tissue and body fluids. As 
can be seen from Table 3, the body tissue appears to be the best specimen to test when looking for 
aflatoxins. In body tissue, 35.7% of the samples were positive whereas nasal secretions and urine did Int. J. Mol. Sci. 2009, 10                 
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not appear to be a good reservoir for aflatoxin detection. As can be seen in Table 4 the urine appears to 
be the best body fluid to test when looking for ochratoxin. In urine, 23.2% of the samples were 
positive, whereas nasal secretions and body tissues did not appear to be good reservoirs for   
ochratoxin detection. 
 
Table 3. Specimen types tested for aflatoxins from patients exposed to molds   
and/or mycotoxins. 
Specimen 
Types 
Negative 
Specimens 
Positive specimens 
≥ 1.0 ppb (ng/mL) 
Number of 
specimens tested 
Urine 120  58  178 
Nasal secretions and sputa  41  6  47 
Tissue block  18*  10**  28 
Other  Ear fluid (1 ) 
Spinal fluid (2 ) 
Bronchial alveolar 
lavage (BAL) (1) 
Vaginal fluid (1) 
5  1 (ear fluid)  7 
Total: 184  75  260 
*Brain (3), liver (4), lung (3), muscle (2), bone marrow clot (1), bladder (1), skin (3), ovary (1). 
** Liver (4), brain (3), lung (2), skin (1) 
 
Table 4. Specimen types tested for ochratoxin A from patients exposed to molds   
and/or mycotoxins. 
Specimen 
Types 
Negative 
Specimens 
Positive specimens  
≥ 2.0 ppb (ng/mL) 
Number of  
specimens tested 
Urine 96  29  125 
Nasal secretions and sputa  26  1 (sputum)  27 
Tissue block  19* 
1 (renal cell 
carcinoma) 
20 
Other 
Ear fluid (1) 
Spinal fluid (2) 
BAL (1) 
4 1  5 
Total 145 32  177 
*Bone marrow clot (1), brain (2), liver (5), lung (5), skin (4), ovary (1), muscle (1). 
  
Table 5 shows the trichothecene levels in specimens from patients exposed to mold and/or 
mycotoxins. As can be seen in this table that if trichothecenes are present in body fluids, urine appears Int. J. Mol. Sci. 2009, 10                 
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to be the best body fluid to test. Trichothecenes were present in urines at levels between 0.2 and 1.0 
ppb in sixty-two percent of the specimens. Although a small sampling is reported in this study, lung 
biopsies showed the presence of trichothecenes in significant numbers of specimens when compared to 
other tissue types. Other significant positive fluids were respiratory samples (e.g., sputa, BAL) and ear 
fluids. One spinal fluid was also positive for trichothecenes. 
 
Table 5. Specimens types tested for macrocyclic trichothecenes from patients exposed to 
molds and/or mycotoxins. 
Specimen types 
Negative 
Specimens 
Positive specimens  
≥ 2.0 ppb (ng/mL) 
Number of 
specimens tested 
Urine 223  437  #  660 
Nasal secretions 
(includes sputa, 
nasal washes, BAL) 
39 24  63 
Tissue  18 *  14 **  32 
Other 5^  9^^  14 
Total: 285  475  769 
#  Sixty-two percent of all positives show 0.2 –1.0 ppb (ng/mL) in urine. 
*  Bladder (1), ovary (1), brain (3), muscle (3), bone marrow clot (1), sinus biopsy (3), liver 
(3), and skin (3).     
** Sinus (2), lung  (7), brain (2), skin (1), liver (1), ovary (1). 
 ^ Spinal fluid (2), feces (1), breast milk (1), vaginal secretions (1).  
 ^^Ear fluid (2), sputum (4), spinal fluid (1), BAL (1). 
 
There have been no previous studies which have demonstrated large numbers of different tissues 
and/or body fluids to be contaminated with mycotoxins. This study shows that mycotoxins can be 
found in tissues and/or body fluids in humans after environmental exposure to toxin producing molds. 
The finding of mycotoxins in these fluids or tissues is consistent with clinical symptoms reported by 
these patients. Respirable trichothecene mycotoxins can be found in the air of Stachybotrys chartarum 
(SC) contaminated buildings [23,24,25]. The symptoms experienced by patients with the presence of 
mycotoxins include nausea, vomiting, ataxia, mental confusion, and variations in blood pressure. 
These symptoms are similar to those experienced by patients when a preparation of diacetoxyscirpenal 
(anguidine) [26] a simple trichothecene, was injected into humans. The symptoms experienced by 
patients in this study are also similar to the symptoms experienced by those individuals in SC infested 
buildings [27]. Brasel et al. [28] reported testing for airborne mycotoxins in non-agricultural settings 
by using competitive ELISA. It has been demonstrated that SC has been shown to grow in buildings 
where people are having health problems [28]. It has also been demonstrated that SC produces 
macrocyclic trichothecene mycotoxins in these buildings where these toxins are definitely inhaled by 
people [13]. These studies confirm that mycotoxins can be detected in human beings in   Int. J. Mol. Sci. 2009, 10                 
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concentrations sufficient to potentially cause the health problems observed in people in mold 
contaminated environments.      
 
 3. Experimental Section  
 
3.1. Samples 
 
Urine and nasal secretions were obtained from hospital patients or out-patients with a history of 
exposure to mycotoxins or fungi. Fixed autopsy and surgical biopsy specimens present in paraffin 
blocks from private autopsy specimens, pathology department surgical specimens, or coroner 
specimens were obtained from patients also with histories of exposure to mycotoxins or fungi. 
Negative control groups (Table 1) were the same type of specimens, but from patients with no known 
exposure to mycotoxins or molds. All specimens were placed into two groups. Group 1 was comprised 
of samples from individuals with no reported symptoms or known fungi or mycotoxin exposure. In this 
group, 55 urines and 27 upper respiratory (nasal washes and sputa) and 15 autopsy/surgical specimens 
were examined for the presence of mycotoxins (aflatoxins, ochratoxins, trichothecenes). Group 2 was 
comprised of samples from individuals with reported exposure to non-identified fungi or chemicals. 
Common symptoms of patients corresponding to group 2 samples included blurred vision, memory 
loss, fatigue, headache, nausea, loss of balance, cognitive deficits, rhinitis, sinusitis, rashes, and 
allergies. A detailed history and symptoms from many of the specimens were provided by many of the 
treating physicians (data not shown). Nasal secretions and washings were obtained by injection of 3-5 
mL of sterile saline into each nostril of a patient. The patient was instructed to hold the saline in the 
nostrils for 30 seconds and then blow the saline into a sterile container held close to the nose. The 
specimen(s) were then collected and placed in containers.  
 
3.2. Validation Samples 
 
Validations were performed in a clinical laboratory for qualitative purposes only. Samples of 
extracted and filtered human heart tissue, liver tissue, urine, and nasal secretions (including sputum) 
were initially tested for the presence of mycotoxins (negative controls).  All were negative for any type 
of mycotoxin tested. These negative control samples of mycotoxins were then spiked with different 
dilutions of aflatoxin (Sigma), ochratoxin (Sigma) roridin A (Sigma) and satratoxin H (Texas Tech 
University Health Sciences Center, Lubbock, TX). Samples were then evaluated for the amount of 
mycotoxin present. All samples were evaluated for the matrix effect by diluting the spiked samples in 
dilutions of 1:3, 1:4, 1:5, 1:6, and 1:10 amounts. Spiked amounts were evaluated as to the amount of 
known samples (mycotoxins) placed in each sample. Conclusions were then made as to which dilution 
for each mycotoxin should be used in the evaluation(s). These spiked amounts were used as calibrators 
to determine the levels of detection of each toxin. Each time a sample was evaluated, calibrators, 
negative, and positive, spiked tissues and fluids were also evaluated. Levels of detection were 
determined by guidelines established by the Clinical and Laboratory Standards Institute (NCCLS), 
document EP-17 A [26], which provide protocols for determining the lower limit of detection of 
clinical laboratory methods. The method in this paper is a qualitative validation, thus, actual values of Int. J. Mol. Sci. 2009, 10                 
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specimens are not given. The EP-17 is intended for use by clinical laboratories for in vitro diagnostic 
tests. There is no claim for limit of quantification (LoQ) in this study. Validations were done as 
directed by the Clinical and Laboratory Standards Institute. Accuracy, precision, analytical sensitivity 
(detection limit) and analytical specificity (interfering substances) were the performance characteristics 
determined in this test. Accuracy was determined by running control samples and spiked samples of 
known amounts of mycotoxins 20 times within a designated run within a given day. Each material was 
also analyzed once per day for 20 days. Results reported were reported as standard deviations in terms 
defined as short term (within-run or within-day) experiment and long-term (between-day) experiment.  
  
3.3. Preparation and evaluation of specimens for mycotoxin detection 
 
Urine was received from a first-voided morning specimen and stored at 1-6 °C. In-house validations 
demonstrated that specimens could be held at 1-6 °C for seven days without affecting the results. 
Specimens were frozen at -20 °C for 24 months. A urine analysis was conducted using a dipstick to 
measure pH, specific gravity, glucose, nitrates, ketones, and blood. The urine was examined for 
sediment and was centrifuged at 2,500 g for 5 minutes (SeroFuge, Clay-Adams, Pesquady, NJ). if 
sediment was present. The pH of the urine was adjusted to 7.2 using a 1:5 dilution of urine-phosphate 
buffered saline (PBS) (pH 7.2) for the trichothecene testing. Nasal secretions and mucous samples as 
well as washes were observed for mucous presence. If mucous was present, a solution of 
MUCOSOL™ (Alpha Tec Systems, Inc. Vancouver, Washington) was prepared and added in equal 
amount of body fluid to Mucosol 
TM. After treatment, the sediment was re-suspended in PBS with a pH 
of 7.2. Tissue was received as either tissue fixed in a 10% formalin solution or in a paraffin-embedded 
tissue block. A minimum of 25-35 mg of formalin-fixed tissue was required for mycotoxin extraction. 
A maximum of 3 grams of formalin-fixed tissue was used if the tissue was in formalin less than three 
months.  Tissue was placed into an autoclaved screw top tube containing silica bead beating glass. The 
specimens were lysed in a methanol/PBS solution optimized for the lysis of tissue and processed 
utilizing a bead-beater instrument (Biospec Products, Bartlesville, OK). The tubes were removed from 
the bead-beater and incubated to complete the lysis of the samples. After incubation, the samples were 
placed in 4.5 mL of PBS pH 7.2. Specimens were tested differently from this point to determine the 
presence of specific mycotoxins.  
One mL of the prepared samples was applied to an IA column containing specific polyclonal 
antibodies directed against aflatoxins B1, B2, G1, and G2. The columns were washed twice with 
distilled water and then eluted with HPLC grade methanol (Sigma). One mL of a dilute bromine 
solution was added to the eluate, mixed, and read by fluorometry (Sigma, St. Louis, Missouri).  Known 
standards of aflatoxin B1, B2, G1, and G2 were used (Trilogy Laboratories, Washington, MO) in 50 
ppb, 25 ppb, and 2.5 ppb amounts.  
One mL of the prepared samples mixed with an 80:20 mixture of methanol and water were applied 
to an IA column containing a specific monoclonal antibody to ochratoxin A. The columns were 
washed twice and eluted with a dilute solution of sodium hydroxide. The eluted samples were then 
read by fluorometry. Known standards of ochratoxin A were used (Trilogy Labs) at 50, 25,   
and 2.5 ppb.    Int. J. Mol. Sci. 2009, 10                 
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Microtiter plates containing antibody to roridin A (a macrocyclic trichothecene) were used in this 
study. One hundred µL of calibrators with either satratoxin H or roridin A were added at 
concentrations from 0, 0.1, 1.0, and 10 ppb as standards for the curve determination.  One hundred µL 
of urine, nasal secretions, or tissue extractions were added to wells. All samples and calibrators were 
done in duplicate. The specimens were then incubated for 15 minutes at 20-25
 °C. Then 100 µL of 
enzyme horse radish peroxidase conjugated with a macrocyclic trichothecene was added and incubated 
for 15 minutes. Wells were washed to remove the unbound material with distilled water with Tween
® 
20. One hundred µL of substrate was then added and incubated for 30 minute at 20-25 °C. On the 
addition of substrate, a color developed, the intensity of which is proportional to the amount of toxin-
enzyme bound to the well; i.e., the color intensity decreases with increasing concentrations of the toxin 
in the sample. Samples were read by spectroscopy at 450 nm. Results of the readings were correlated 
to a standard curve which gives a result in parts per billion (ppb). Standards of roridin A and/or 
satratoxin H were used (Trilogy Labs and RealTime Laboratories, LLC, Dallas,TX). The limit of 
detection was determined by spiking samples with known amounts of trichothecene (either satratoxin 
or roridin) and determining the lowest concentration that is detected. 
 
4. Conclusions  
 
Mycotoxins, specifically trichothecenes, aflatoxins, and ochratoxins, can be detected in human 
tissue and body fluids in patients who have been exposed to toxin producing molds in their 
environment. The toxins can be best determined in urine as a screening qualitative test which can assist 
the physician to determine what the best mode of therapy would be.    
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